Navigation Links
Study: Higher Hepatitis C Infection During Acupuncture in Asian Americans; polyDNA Recommends That Doctors Prescribe Gene-Eden-VIR against HCV

Rochester, NY (PRWEB) December 04, 2013

Acupuncture is one of the greatest risk factor among Asians for acquiring a Hepatitis C (HCV) infection. Results of a study “con?rmed ?ndings from prior cross-sectional studies of patients with chronic hepatitis C and similarly suggested that certain non-traditional risk factors such as acupuncture or exposure to contaminated needles are probable causes of HCV infection. In addition, acupuncture or exposure to dirty needles is a strong independent predictor of positive anti-HCV test results in Asians (1).”

Part of the reason acupuncture is a higher risk factor among Asian Americans than among other population groups is due to the role acupuncture plays in traditional Asian communities. Researchers found that “the difference in risk factors between Asian and non-Asian HCV patients could be due to … exposure to contaminated needles, since these tend to occur in more routine and casual settings in Asian communities (1).”

This is alarming since researchers showed in a study that Asians have a much higher risk of liver cancer than other ethnicities if they are infected with HCV. As study authors wrote, “Asian patients with chronic hepatitis C and cirrhosis have four times the risk of liver cancer compared to Caucasians, and twice the risk compared to non-Hispanic African Americans (1).”

In addition, the prevalence of HCV in Asian Americans is much higher than the national average. In fact, studies have shown that up to 6% of Asian Americans have HCV (1). “Preliminary studies from New York, Texas, Virginia, and California…have suggested a prevalence range from 2.2 - 6% in Asian Americans. This prevalence range is much higher than the national prevalence of 1.3% found in the National Health and Nutritional Examination Survey… (1).”

“We recommend that Asian Americans take Gene-Eden-VIR, a natural remedy designed to help the immune system target the latent HCV.” – Mike Evans, polYDNA

A study published on August 12, 2013 in the peer reviewed, medical journal
Pharmacology & Pharmacy, in a special edition on Advances in Antiviral Drugs, showed that Gene-Eden-VIR reduced HCV symptoms. Study authors wrote that, “Individuals infected with the hepatitis C virus…reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR (2).” The study authors also wrote that, “We observed a statistically significant decrease in the severity, duration, and frequency of symptoms (2).”

To learn more about Gene-Eden-VIR, and HCV visit All orders of Gene-Eden-VIR are completely confidential, and no information is shared or sold to any third party. Privacy is assured.


(1) Less-established risk factors are common in asian americans with hepatitis C virus: a case-controlled study. Published in November 2013.

(2) Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published August 12, 2013.

polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.

polyDNA developed Gene-Eden-VIR, an antiviral natural remedy that helps the immune system kill latent viruses.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Breaking Study: ICU Medicals Tego® Needlefree Connector Proves More Cost Effective Than Traditional Central Venous Catheter Locks
2. Nature Materials study: Graphene invisible to water
3. New Study: Health Professionals Support Biotechnologys Use In Food Products And Sustainable Farming
4. Nature Materials study: Boosting heat transfer with nanoglue
5. RPCI-Led Study: FAK Inhibitor Proves Effective Against Brain Tumors in Preclinical Studies
6. Study: Brain Imaging After Mild Head Injury/Concussion Can Show Lesions
7. New Study: Valtrex (Valacyclovir) Side Effects Target the Brain; polyDNA Suggests a Natural Herpes Remedy
8. Study: FOLFIRINOX Followed by Chemoradiation Shows Substantial Activity in Locally Advanced Pancreatic Cancer
9. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
10. Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
11. California Biomedical Companies Report Higher Product Approvals, Fewer Delays
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... be speaking at the following conference, and invited investors ... York, NY      Tuesday, December 1, 2015 at ... York, NY      Tuesday, December 1, 2015 at ... Healthcare Conference, New York, NY ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... the year and one of the premier annual events for pharmaceutical manufacturing: 2015 ... 8–11 November 2015, where ISPE hosted the largest number of attendees in more ...
(Date:11/24/2015)... ... 2015 , ... This fall, global software solutions leader SAP and AdVenture Capital ... and pitch their BIG ideas to improve health and wellness in their schools. , ... win the title of SAP's Teen Innovator, an all-expenses paid trip to Super Bowl ...
(Date:11/24/2015)... 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its ... at 11:00 a.m. Israel time, at the law ... Allon Street, 36 th Floor, Tel Aviv, Israel ... and Izhak Tamir to the Board of Directors; ... directors; , approval of an amendment to certain terms of options ...
Breaking Biology Technology:
(Date:11/17/2015)... -- Vigilant Solutions announces today that Mr. Dick W. ... --> --> Mr. Boyce ... at TPG Capital, one of the largest global investment ... revenue.  He founded and led TPG,s Operating Group, which ... 1997 to 2013.  In his first role, he served ...
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
Breaking Biology News(10 mins):